FIELD: biotechnology.
SUBSTANCE: invention relates to a protease-activated bispecific molecule which contains a first antigen-binding fragment having the ability to specifically bind to CD3, and a second antigen-binding fragment having the ability to specifically bind to FolRl, as well as to a pharmaceutical composition containing it.
EFFECT: invention is effective for preparing a drug for treating or slowing down the progression of cancer.
20 cl, 44 dwg, 4 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION | 2014 |
|
RU2727836C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2017 |
|
RU2827545C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES | 2020 |
|
RU2831608C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| BISPECIFIC ANTIBODIES TO Vβ17/CD123 | 2020 |
|
RU2831786C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
